Deborah S. Yokoe*

, Gary A. Noskin†, Susan M. Cunningham†, Gianna Zuccotti‡, Theresa Plaskett‡, Victoria J. Fraser§, Margaret A. Olsen§, Jerome I. Tokars¶, Steven Solomon¶, Trish M. Perl#, Sara E. Cosgrove#, Richard S. Tilson*, Maurice Greenbaum**, David C. Hooper††, Kenneth E. Sands‡‡, John Tully§§, Loreen A. Herwaldt¶¶, Daniel J. Diekema¶¶, Edward S. Wong##, Michael Climo##, and Richard Platt***
Author affiliations: *Brigham and Women's Hospital, Boston, Massachusetts, USA; †Northwestern University, Chicago, Illinois, USA; ‡Memorial Sloan-Kettering Cancer Center, New York, New York, USA; §Washington University School of Medicine, St. Louis, Missouri, USA; ¶Centers for Disease Control and Prevention, Atlanta, Georgia, USA; #Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; **North Shore Medical Center-Salem Hospital, Salem, Massachusetts, USA; ††Massachusetts General Hospital, Boston, Massachusetts, USA; ‡‡Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; §§Mount Auburn Medical Center, Cambridge, Massachusetts, USA; ¶¶University of Iowa Carver College of Medicine, Iowa City, Iowa, USA; ##McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA; ***Harvard Pilgrim Health Care, Boston, Massachusetts, USA
Main Article
Table 4
Percentage of patients who met the antimicrobial drug, diagnosis code–screening criteria, or both, after CABG procedures, cesarean delivery, and breast proceduresa
| Procedure and phase |
% of patients meeting
|
| Antimicrobial exposure criteria |
Diagnosis code criteria |
Antimicrobial exposure
or diagnosis code criteria |
| CABG |
| Phase 1 |
15.2 |
4.5 |
15.8 |
| Phase 2 |
19.1 |
4.6 |
19.6 |
| Cesarean delivery |
| Phase 1 |
8.8 |
3.2 |
9.5 |
| Phase 2 |
12.7 |
6.4 |
14.1 |
| Breast procedures |
| Phase 1 |
3.5 |
0.8 |
3.7 |
| Phase 2 |
6.7 |
2.0 |
6.8 |
Main Article
Top of Page